Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Gains from Investment Securities (2022 - 2025)

Historic Gains from Investment Securities for bioAffinity Technologies (BIAF) over the last 4 years, with Q3 2025 value amounting to $58031.0.

  • bioAffinity Technologies' Gains from Investment Securities fell 3625.63% to $58031.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $342310.0, marking a year-over-year decrease of 68.79%. This contributed to the annual value of $361181.0 for FY2024, which is 28737.53% up from last year.
  • bioAffinity Technologies' Gains from Investment Securities amounted to $58031.0 in Q3 2025, which was down 3625.63% from $92975.0 recorded in Q2 2025.
  • Over the past 5 years, bioAffinity Technologies' Gains from Investment Securities peaked at $2.0 million during Q2 2023, and registered a low of $1655.0 during Q1 2023.
  • Moreover, its 4-year median value for Gains from Investment Securities was $81601.5 (2023), whereas its average is $195127.2.
  • In the last 5 years, bioAffinity Technologies' Gains from Investment Securities skyrocketed by 2790336.04% in 2023 and then crashed by 9547.8% in 2024.
  • bioAffinity Technologies' Gains from Investment Securities (Quarter) stood at $26692.0 in 2022, then surged by 179.25% to $74538.0 in 2023, then increased by 22.14% to $91038.0 in 2024, then crashed by 36.26% to $58031.0 in 2025.
  • Its last three reported values are $58031.0 in Q3 2025, $92975.0 for Q2 2025, and $100266.0 during Q1 2025.